Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The reproducibility of biomedical research on novel drug targets has become suspect. Here, we highlight how drug discovery centres embedded in academic institutions, but with a translational imperative, can help address this reproducibility crisis.
Digital prescription pills, set to hit the market soon, offer the opportunity to address key drug adherence challenges in clinical practice and clinical trials.
First pivotal study win for Merck & Co.'s antibacterial antibody suggests that biologics could at last bring precision medicine to the anti-infective space.
Husseini Manji, the Global Therapeutic Area Head of Neuroscience at Janssen, discusses the promise of NMDA receptor antagonists, anti-inflammatories and endocannabinoid modulators in psychiatry.
This analysis provides an overview of the current pipeline of drugs for psoriasis and an outlook for the psoriasis market, which is growing substantially.
The quality of the chemical starting points for small-molecule drug discovery is a key factor in improving the likelihood of clinical success. In this article, experts from several organizations involved in drug discovery for malaria, tuberculosis and neglected tropical diseases present disease-specific criteria for hits and leads, and discuss the underlying rationale.
The misfolding and aggregation of specific proteins — a process known as amyloidogenesis — seem to underlie a range of degenerative disorders. Here, Kelly and colleagues discuss the current understanding of the process and pathological role of protein aggregation, focusing on emerging disease-modifying strategies to ameliorate aggregation-associated degenerative disorders.
Targeted delivery to the lymphatic system has the potential to improve bioavailability, enhance prophylactic and therapeutic vaccination or tolerance induction, and target drug delivery to lymph-resident infection or metastasis. In this Review, Trevaskis, Kaminskas and Porter provide an overview of lymphatic targeting and delivery strategies in drug development, and discuss the clinical applications of these approaches.
